Non-invasive, fully automated system for the accurate assessment of: cardiovascular/diabetic autonomic neuropathy, effectiveness of beta-blocker therapy, and risk stratification of sudden cardiac death
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of Intellewave plus 4970 other startups.
